Design and Statistical Issues Related to Testing Experimental Therapy in Multiple Sclerosis. In: Rudick RA, Goodkin DE, editors. Treatment of Multiple Sclerosis. London: Springer; 1992. pp. 91-122. [DOI: 10.1007/978-1-4471-3184-7_4]

Glucocorticosteroid therapy for multiple sclerosis: a critical review

Controversy remains as to the efficacy, route of administration and dose of glucocorticosteroid (GCS) in multiple sclerosis (MS) therapy. With the recent approval of new disease modifying treatments and increasing interest in cost-benefit assessments, it is timely to critically consider their role in MS therapeutics. In this paper we review our current understanding of the cellular and molecular mechanisms of action of GCS as they relate to the postulated pathophysiology of MS. We also critically review the use of glucocorticosteroid therapy to: (1) improve recovery from exacerbations of MS, (2) delay the onset of MS in patients who experience a first episode of monosymptomatic optic neuritis, and (3) delay the time to onset of sustained progression of disability in patients with clinically definite MS.